Werewolf Therapeutics: Wtx-124 Shown to Be Clinically Active and Generally Well-Tolerated in Patients
Werewolf Therapeutics to Present Data From Ongoing Phase 1/1B Clinical Trial of Wtx-124 as Monotherapy and in Combination With Pembrolizumab in Solid Tumors
Y-mAbs Announces Publication of Preclinical GD2-Sada Data at 2024 Asco Annual Meeting
Suntory Says the Company Is Not in Negotiations With Boston Beer About Acquisition
Nuvation Bio Inc : Aim to Become a Commercial-Stage Organization by End of 2025
Nuvation Bio: Look Forward to Further Advancing Taletrectinib and Plan to Share Results From Global, Pivotal Trust-II Study by End of 2024
Nuvation Bio Inc : Responses Were Durable With Long-Term Follow-up; 71% of Tki-Naïve Patients Were Still Progression-Free at Two Years
Nuvation Bio Inc : Tumors Shrank in 91% of Taletrectinib-Treated Patients With Advanced Ros1-Positive Nsclc Who Were Ros1 Tki-Naïve
Nuvation Bio Announces Data From Pivotal Phase 2 Trust-I Study of Its Investigational Ros1 Inhibitor, Taletrectinib, Are Published in the Journal of Clinical Oncology and Reported at 2024 Asco Annual Meeting
Jazz Pharmaceuticals: Results Highlight Clinically Meaningful Benefits of Sustained and Durable Responses With Continued Treatment With Zanidatamab
Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 Asco Annual Meeting
Krazati (Adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients With Pretreated Locally Advanced or Metastatic Krasg12C-Mutated Non-Small Cell Lung Cancer
Tiumbio Co Ltd : Data From Full Phase 1B Trial, Which Includes 18 Patients, Will Be Available in Second Half of 2024
Tiumbio Co: Tu2218 Was Well-Tolerated as a Monotherapy and Combination Therapy With Pembrolizumab, With No Dose Limiting Toxicities (Dlts) to Date
Eli Lilly : Data Demonstrated Promising Monotherapy Activity With Olomorasib Across a Range of Kras G12C-Mutant Solid Tumors
Jazz Pharmaceuticals Presents Overall Survival and Longer Follow-up Data From Herizon-BTC-01 Trial Evaluating Zanidatamab in Previously Treated Her2-Positive Biliary Tract Cancer at Asco 2024
Kymera Therapeutics: KT-253 Was Generally Well Tolerated Without Hematologic Adverse Events Seen With Traditional Mdm2 Small Molecule Inhibitors
Kymera Therapeutics Inc : KT-253 Phase 1 Study Ongoing With Additional Data Expected in Second Half of 2024
Pfizer Inc : Third Phase 3 Trial in Third Type of Lymphoma to Show Improvement in Overall Survival With an Adcetris-Containing Regimen
Immunocore Presents Kimmtrak Clinical Data Demonstrating That Patients With Stable Disease and Confirmed Tumor Reduction Have Similar Clinical Outcomes to Patients With Partial Response
Gilead and Arcus Announce Anti-Tigit Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper Gi Cancers
Ivonescimab Manuscript for Harmoni-a Clinical Trial Results Published in Jama
Pfizer’s Adcetris® Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (Dlbcl)
Takeda and Pfizer Announce Four-Year Results From Positive Phase 3 Hd21 Trial of Additional Adcetris® (Brentuximab Vedotin) Combination in Frontline Hodgkin Lymphoma
Kymera Therapeutics Presents New Clinical Data From Ongoing Phase 1 Trial of Mdm2 Degrader KT-253 at Asco Annual Meeting
Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at Asco 2024 Demonstrating Cm24 Improved Overall Survival and Other Efficacy Endpoints in Pancreatic Cancer
Delta Air Lines CEO: Encouraged by the Steps Boeing Company Is Taking With New Chairman, Changes
Delta Air Lines CEO: Still Committed to the Boeing Max 10, but Doesn’t Anticipate Getting Them for Some Time
U.S.-Egypt-Israel Meeting Scheduled Sunday in Cairo to Discuss Reopening of Rafah Crossing With Gaza - Source to Egypt's State-Linked Al Qahera TV
Cullinan Therapeutics Announces Positive Initial Data From Pivotal Phase 2B Rezilient1 Study of Zipalertinib